[1]原 宁,宁 萍.微生态制剂联合奥美拉唑序贯治疗幽门螺旋杆菌阳性消化性溃疡效果及对患儿丙二醛、转化生长因子β1蛋白水平和肠道菌群的影响[J].陕西医学杂志,2021,50(4):472-475.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.023]
　YUAN Ning,NING Ping.Effect of probiotics combined with omeprazole sequential therapy in treatment of Helicobacter pylori-positive peptic ulcer and its influence on MDA,TGF-β1 protein levels and intestinal flora in children[J].,2021,50(4):472-475.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.023]
点击复制

微生态制剂联合奥美拉唑序贯治疗幽门螺旋杆菌阳性消化性溃疡效果及对患儿丙二醛、转化生长因子β1蛋白水平和肠道菌群的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年4期
页码:
472-475
栏目:
药物与临床
出版日期:
2021-04-05

文章信息/Info

Title:
Effect of probiotics combined with omeprazole sequential therapy in treatment of Helicobacter pylori-positive peptic ulcer and its influence on MDA,TGF-β1 protein levels and intestinal flora in children
作者:
原 宁; 宁 萍
(渭南市妇幼保健院儿科,陕西 渭南 714000)
Author(s):
YUAN Ning; NING Ping
(Department of Pediatrics,Weinan Maternal and Child Health Hospital,Weinan 714000,China)
关键词:
奥拉美唑;  序贯疗法;  微生态制剂;  HP阳性;  消化性溃疡;  肠道菌群;  丙二醛;  转化生长因子β1蛋白;  复发
Keywords:
Olameazole;  Sequential therapy;  Probiotics;  HP positive;  Peptic ulcer;  Intestinal flora;  Malondialdehyde;  Transforming growth factor β1 protein;  Relapse
分类号:
R 573.1
DOI:
DOI:10.3969/j.issn.1000-7377.2021.04.023
文献标志码:
A
摘要:
目的:探究微生态制剂联合奥美拉唑序贯疗法治疗幽门螺旋杆菌(HP)阳性消化性溃疡的效果及对患儿丙二醛(MDA)、转化生长因子β1(TGF-β1)蛋白水平和肠道菌群的影响。方法:纳入小儿消化性溃疡(PU)患儿120例,随机分为序贯组和微生态制剂组,各60例。序贯组使用奥美拉唑序贯疗法,微生态制剂组在序贯组的基础上间隔2 h后使用双歧杆菌四联活菌片。比较两组的疗效,MDA、TGF-β1水平,HP根除率、溃疡愈合率、复发率,肠道菌群变化以及不良反应发生率。结果:微生态制剂组的治疗有效率明显高于序贯组(P<0.05)。治疗后,微生态制剂组MDA、TGF-β1水平、复发率、不良反应发生率均明显低于序贯组(均P<0.05)。微生态制剂组HP根除率和溃疡愈合率均明显高于序贯组(均P<0.05)。治疗后,微生态制剂组双歧杆菌、肠球菌、类杆菌和定植抗力(B/E)均明显高于序贯组,肠杆菌明显低于序贯组(均P<0.05)。结论:奥美拉唑序贯疗法联合微生态制剂治疗HP阳性PU,疗效确切,能够有效减轻机体炎症反应,促进HP的根除,降低复发率,维持肠道菌群的平衡,且安全性好。
Abstract:
Objective:To study the effect of probiotics combined with omeprazole sequential therapy in the treatment of Helicobacter pylori(HP)-positive peptic ulcer(PU)and its influence on the level of MDA,TGF-β1 and intestinal flora in children.Methods:120 children with PU were included and randomly divided into sequential group and probiotic group,60 cases in each group.Sequential group was treatment with omeprazole sequential therapy,and probiotic group was treatment with bifidobacteria quadruple viable tablets after 2 hours on the basis of sequential group.The curative effects,the levels of MDA and TGF-β1,HP eradication rate,ulcer healing rate,recurrence rate,changes of intestinal flora and the incidence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in the probiotic group was significantly higher than that in the sequential group(P<0.05).After treatment,the levels of MDA and TGF-β1,recurrence rate,and incidence of adverse reactions in the probiotic group were significantly lower than those in the sequential group(all P<0.05).The HP eradication rate and ulcer healing rate in the probiotic group were significantly higher than those in the sequential group(all P<0.05).After treatment,Bifidobacterium,Enterococcus,Bacteroides and B/E in the probiotic group were significantly higher than those in the sequential group,and Enterobacter was significantly lower than that in the sequential group(all P<0.05).Conclusion:Omeprazole sequential therapy combined with probiotics in the treatment of HP-positive PU has a definite effect.It can effectively reduce the body's inflammatory response,promote the eradication of HP,reduce the recurrence rate,maintain the balance of intestinal flora,and has good safety.

参考文献/References:

[1] 何荣香,俞 丹,何 英,等.枸橼酸铋钾联合奥美拉唑四联疗法治疗小儿消化性溃疡临床效果及与血清MDA、LPO和NO的相关性研究[J].临床误诊误治,2019,32(6):23-27.
[3] 梅玲华,贺兆平,杨永宏,等.含铋剂四联疗法对幽门螺杆菌阳性小儿消化性溃疡的疗效观察[J].现代消化及介入诊疗,2019,24(4):73-76.
[3] 卜 爱,杜 姗.艾司奥美拉唑镁肠溶片治疗幽门螺杆菌相关性胃溃疡临床研究[J].陕西医学杂志,2019,48(10):1381-1383.
[4] 谢 佳,凌 涛,杨 兵.益生菌辅助治疗消化性溃疡的研究进展[J].中华生物医学工程杂志,2016,22(4):343-346.
[5] 《中华儿科杂志》编辑委员会.小儿慢性胃炎、消化性溃疡胃镜诊断标准[J].中华儿科杂志,2003,41(3):189.
[6] 钱小棋,陈玲玲,钟海兵.益生菌联合抗幽门螺杆菌治疗对消化性溃疡患者的疗效[J].中国微生态学杂志,2018,30(2):189-192.
[7] 马 艳,毛志田.香砂六君子汤联合西药治疗HP阳性脾胃虚弱型消化性溃疡临床研究[J].陕西中医,2020,41(3):357-359.
[8] 赵靖涛,樊 玲,张 意,等.幽门螺杆菌感染根除后复发及其影响因素的研究[J].胃肠病学,2020,25(2):104-108.
[9] 马志爽,李 勇.铋剂四联疗法与序贯疗法治疗幽门螺杆菌感染的Meta分析[J].中国药物评价,2017,34(5):376-380.
[10] 尉佳林,余发全,何桂榕,等.埃索美拉唑为基础的四联疗法对消化性溃疡患者幽门螺杆菌根除率、炎性因子及生活质量的影响[J].现代生物医学进展,2019,19(18):195-198.
[11] 朱香丽,刘 峥,吴忠强,等.不同治疗方案对儿童幽门螺杆菌感染的临床疗效评价[J].中国当代儿科杂志,2017,19(6):672-676.
[12] 张俊璇,方超然,时鑫鑫,等.根除幽门螺杆菌治疗药物的研究进展[J].医学综述,2020,26(2):316-321.
[13] 叶娟娟,赵 梦.固肠胶囊联合双歧杆菌四联活菌片治疗IBS-D疗效及对患者肠道菌群,肠黏膜屏障功能的影响[J].药物流行病学杂志,2019,28(5):15-19.
[14] 蔡少薇,王伟福,郭婉薇,等.枸橼酸铋钾调控NADPH氧化酶参与的氧化应激改善老年消化性溃疡的疗效[J].广西医科大学学报,2019,36(6):1010-1012.
[15] 余 明,王 博,张亚飞,等.癌前病变及胃癌与幽门螺杆菌感染的关系探讨[J].陕西医学杂志,2018,47(11):1424-1426.
[16] 刘玉明,谢 露,杜建英.三种疗法根除儿童幽门螺杆菌感染的疗效观察[J].中国临床医生杂志,2015,43(6):79-82.
[17] 胡佳丽,兰春慧,张昊翔,等.不同疗程铋剂四联疗法在中国根治幽门螺杆菌感染疗效的Meta分析[J].第三军医大学学报,2017,39(10):1044-1055.
[18] 时玉华,王丽娜,史增辉,等.镶嵌疗法联合中药对H.pylori阳性消化性溃疡炎性相关因子及复发的影响[J].河北医药,2020,42(1):66-69.
[19] 刘宏健.幽门螺杆菌根除治疗对功能性消化不良儿童肠道微生态及胃肠激素的影响研究[J].中国医学创新,2020,17(7):48-52.
[20] 王文妤,蒋丽蓉,邓朝晖.双歧杆菌三联活菌散联合三联疗法治疗儿童幽门螺杆菌感染的临床疗效观察[J].儿科药学杂志,2017,23(7):8-12.

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2015SF129)
更新日期/Last Update: 2021-04-06